Our mission is to improve the prognosis of patients with brain diseases by increasing the permeability of cerebral blood vessels to allow therapeutic molecules such as antibodies, pathway inhibitors, chemotherapies or enzymes to reach effective concentrations in brain.
ERYTECH’s therapeutics are derived from a proprietary technology platform, ERYCAPS, which encapsulates compounds in red blood cells. Our lead program, eryaspase(GRASPA®) encapsulates asparaginasein donor red blood cells. This novel treatment targets solid and liquid tumors acting on “tumor starvation” pathways while increasing the duration of efficacy and significantly reducing the toxicity profile.
Fab'entechdevelops and manufactures specific polyclonal immunotherapies to address situations of emergency. In addition, Fab'entechalso recently decides to apply its technology on other medical needs and to focus on intoxications with antidote candidates in the fields of biodefense, drug intoxication, anti-venom and nosocomial infections.
GamaMabsis a clinical-stage immuno-oncology biotech developing first-in-class optimized antibodies targeting AMHRII, a new tumor antigen expressed in many cancers such as ovarian, cervix, colorectal, lung, renal, endometrium and liver cancers.
GeNeuro is a clinical-stage biopharmaceutical company focused on stopping autoimmune and neurodegenerative diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA.
Genkyotexis a clinical stage biopharmaceutical company developing breakthrough NOX driven therapies. The Company is currently developing therapies for liver, kidney and lung fibrosis.
Develop breakthrough therapies in fibrotic diseases and for the treatment of certain forms ofmucopolysaccharidosis(MPS). In fibrotic diseases,we focus on nonalcoholic steatohepatitis (NASH) and systemic sclerosis (SSc),two diseases with no approved drugs and high unmet medical needs. In MPS, we currently target
firstMPS VI (MaroteauLamysyndrome),a rare and deadly genetic disease with no satisfactory treatment options.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA is expected to start in 2018, a phase 1-2 clinical trial in GM1 Gangliosidosis in 2019, while we are currently collaborating to define the clinical development path for the treatment of Fragile X syndrome.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience.
The mission of Nosopharmis to discover and develop novel first-in-class anti-infective agents addressing the treatment of severe and life-threatening multidrug-resistant hospital-acquired infections.
OSE Immunotherapeuticsis a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
Disrupt influenza prevention, with a universal Flu vaccine to be combined with commercialized Flu vaccines to drastically improve efficacy and develop vaccines against infectious diseases and cancer immunotherapies, using a unique and proprietary technology platform triggering CD8 T-cell immunity.
Pharmaleadsdevelops proprietary new chemical entities to alleviate severe pain, acute or chronic, without the side effects of opiates and other current treatments. Our compounds are ideally positioned to combat the opioid crisis, which costs billions to the United States.
Poxeluses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH).
To create a world of bionic vision for those who have lost their sight, via best in class bionic vision systems that interface the eye with the brain, and enable the blind to regain greater autonomy and improved quality of daily living.
Stems develops, manufactures and commercializes sterile, single-use medical devices for autologous fat grafting (lipofilling) in plastic and reconstructive surgery field. Stems also develops osteoarthritis and erectile dysfunction treatments based on the regenerative properties of adipose tissue.
On top of developing, manufacturing and commercializing IVD diagnostics, Theradiaginnovates and develops theranosticstests that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiagis actively participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance.
Theraclion develops, manufactures and markets the Echopulse®medical device for the non-invasive, outpatient treatment of breast fibroadenomas and benign thyroid nodules. Theraclion is currently completing the first ever human study on veins with HIFU.
Theranexusidentifies and develops innovative drug combination for the treatment of neurological disorders. Thanks to its proprietary technology, Theranexusoffers drug candidates with a superior efficacy over the current treatments, while the choice made to use drug repositioning allows to decrease time, costs and risks.